The advancement of pancreatic stem cell research has far reaching benefits to the understanding and treatment of diabetes and other metabolic disorders. Cell replacement therapy through islet transplantation is considered a potential long-term approach to the control of blood glucose levels; however, obtaining sufficient quantities of insulin-producing tissues for islet transplantation remains a major impediment. Stem cells (either from embryonic stem cells or from pancreatic progenitors) potentially provide an abundant alternative source of islet cells for transplantation therapies.
Millipore has introduced progenitor-rich pancreatic cell lines, optimized media, characterization kits, and detection kits to make research in this area more convenient and accessible.
|